Coronavirus antibodies remain stable 7 months after infection

Researchers say common cold antibodies may also help body fight Covid-19

Research suggests antibodies developed after catching the common cold could help protect against Covid-19. Getty

Human antibodies produced to fight the virus that causes Covid-19 remain stable and may even increase seven months after infection, a new study suggests.

Researchers from Barcelona Institute for Global Health (ISGlobal) conducted a review on the duration of immunity to SARS-CoV-2 and the role of pre-existing antibodies against similar coronaviruses that cause common colds.

They examined blood samples from 578 healthcare workers taken at four intervals between March and October 2020 that showed a robust response to the SARS-CoV-2 spike protein.

The results, published in Nature Communications, support the theory that pre-existing antibodies against common cold coronaviruses could protect people against Covid-19.

Researcher Dr Carlota Dobano and her team followed a cohort of healthcare workers at Barcelona Hospital Clinic from the beginning of the pandemic, to evaluate the levels of IgG antibodies against different Covid-19 antigens over time.

“This is the first study that evaluates antibodies to such a large panel of SARS-CoV-2 antibodies over seven months,” she said.

Dr Gemma Moncunill, a co-author of the study, said: “Rather surprisingly, we even saw an increase of IgG anti-spike antibodies in 75 per cent of the participants from month five onwards, without any evidence of re-exposure to the virus.”

A National Health Service worker prepares for patients at a pop-up vaccination centre during a four-day Covid-19 vaccine festival in Langdon Park, east London.

Young people line up to receive shots of Sinovac's Covid-19 vaccine at the Phnom Penh Thmey Health Centre, in Phnom Penh, Cambodia.

People wearing face masks as a precaution against the coronavirus pray during a service at the Chogyesa temple in Seoul, South Korea.

Passengers wearing face masks wait in the outbound queue at Frankfurt airport, in Germany.

Demonstrators clash with police at the end of a national day of protest against French legislation making a Covid-19 health pass compulsory to visit a cafe, board a plane or travel on an inter-city train, in Paris.

A woman takes a selfie while receiving the first dose of the Moderna vaccine against Covid-19, during the vaccination day called 'Vacunaton', which aims to immunise 50,000 Hondurans aged over 35 in the National Stadium, in Tegucigalpa.

A volunteer holds up a sign to remind people to adhere to Covid-19 protocols during round 4 of the men’s golf individual stroke play during the Tokyo 2020 Olympic Games at the Kasumigaseki Country Club in Kawagoe.

A man with a notice walks around people wearing face masks as a precaution against the coronavirus during a service at the Chogyesa temple in Seoul, South Korea.

A demonstrator kicks away a smoking teargas shell during a national day of protest against compulsory Covid-19 vaccinations for certain workers and the compulsory use of health passes, in Paris.

A health worker, right, administers the Sinovac vaccine during a mass vaccination drive against the Covid-19 coronavirus outbreak in Jakarta.

Results also suggested antibodies against human cold coronaviruses (HCoV) could confer cross-protection against Covid-19 infection or disease.

The authors also discovered that people infected by SARS-CoV-2 had lower levels of HCoV antibodies, and that the level of antibodies was higher in asymptomatic carriers than in those with symptoms.

“Although cross-protection by pre-existing immunity to common-cold coronaviruses remains to be confirmed, this could help explain the big differences in susceptibility to the disease within the population,” Dr Dobano said.